Evolution Large Pharma Summit 2023 | Marcus Evans Group | 11 September 2023 | Park Hyatt Aviara Resort, Golf Club & Spa, 7100 Aviara Resort Drive, Carlsbad, CA 92011, USA

This Event Is an Invitation-only, Premium Summit Bringing Leading Clinical Trial Executives and Innovative Suppliers and Solution Providers Together. The Summit’s Content is Aligned With Key Clinical Trial Challenges and Interests, Relevant Market Developments, and Practical and Progressive Ideas and Strategies Adopted by Successful Pioneers.

2023 Speakers

Rachel Soon
Director, Clinical Innovation, Janssen R&D

John Makowski
Vice President, Head of Clinical Operations, Astellas Gene Therapies

Marco Mancini
Director, Global Development Operations & Portfolio Management, Regeneron Pharmaceuticals

Michael Lim
Executive Director, Oncology Franchise Head, Gilead Sciences, Inc.

Tiffany Valentine
Associate Director, Clinical Operations Evolution Lead, Bristol-Myers Squibb

Christine Von Raesfeld
Patient Advocate and Founder and CEO, People with Empathy

Estela Mata-Carcamo
Patient Advocate and President, Looms for Lupus, Inc.

Rachel Soon
Director, Clinical Innovation, Janssen R&D

John Makowski
Vice President, Head of Clinical Operations, Astellas Gene Therapies

Marco Mancini
Director, Global Development Operations & Portfolio Management, Regeneron Pharmaceuticals

Michael Lim
Executive Director, Oncology Franchise Head, Gilead Sciences, Inc.

Tiffany Valentine
Associate Director, Clinical Operations Evolution Lead, Bristol-Myers Squibb

Christine Von Raesfeld
Patient Advocate and Founder and CEO, People with Empathy

Estela Mata-Carcamo
Patient Advocate and President, Looms for Lupus, Inc.

Renee Smith, MBA
Head of Early Development Capabilities and Alliances, The Janssen Pharmaceutical Companies of Johnson & Johnson

Jill Kearney
Global Operations Head, Oncology Early Development, The Janssen Pharmaceutical Companies of Johnson & Johnson

Laura Vessey
Senior Director, Head of Early Development and Clinical Pharmacology, The Janssen Pharmaceutical Companies of Johnson & Johnson

Ting Wang
Senior Director, Clinical Biomarker Operations, Genentech, Inc.

Sidharth Jain
Head, Global Development Data Science, Janssen R&D

Wendy Cheung
Global Head of Oncology Strategy, Operations & New Product Planning, Sanofi

Nishtha Jain
Head of Innovation and Digital Technology, Takeda

Ting Wang
Senior Director, Clinical Biomarker Operations, Genentech, Inc.

Donna Rycroft
Director, Study Risk Management, Clinical Development Operations, AbbVie

Sidharth Jain
Head, Global Development Data Science, Janssen R&D

Lisa Tindell
Vice President, Clinical Research Operations, Minneapolis Heart Institute Foundation

Wendy Cheung
Global Head of Oncology Strategy, Operations & New Product Planning, Sanofi

Nishtha Jain
Head of Innovation and Digital Technology, Takeda

Donna Rycroft
Director, Study Risk Management, Clinical Development Operations, AbbVie

Denise Windenburg, MHA
Director, Clinical Research Operations Effectiveness, Minneapolis Heart Institute Foundation

Anna Hassinger
Director, Clinical Operations, Astellas Gene Therapies

Dr Rajbir Singh, MBBS
Executive Director, Precision Medicine and Health Equity Trials Design, Meharry Medical College

Anil Shanker
SVP, Research and Innovation, Meharry Medical College

DYNAMIC MODERATORS:

Renee Smith
Head of Early Development Capabilities and Alliances, The Janssen Pharmaceutical Companies of Johnson & Johnson

Jill Kearney
Global Operations Head, Oncology Early Development, The Janssen Pharmaceutical Companies of Johnson & Johnson

Laura Vessey
Senior Director, Head of Early Development and Clinical Pharmacology